Physician profile
Abdullah Alshammaa
NPI 1073908869
$1,389.83
in general payments reported to CMS, 2019-2025
13 companies · $19.34 in 2025
The $19.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $19.59 · 2021: $235 · 2022: $137 · 2023: $718 · 2024: $118 · 2025: $19.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $446.37 | 2022-2024 | Briviact |
| Neurelis, INC. | $193.63 | 2023 | Valtoco |
| Eisai INC. | $161.75 | 2019-2024 | |
| Neuropace, INC. | $151.92 | 2023 | |
| Sk Life Science, INC. | $145.22 | 2021-2023 | |
| Livanova USA, INC. | $136.49 | 2021 | |
| Celgene Corporation | $48.95 | 2023-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $19.59 | 2020 | |
| Boston Scientific Corporation | $18.94 | 2024 | |
| Argenx US, INC. | $18.91 | 2023 | Vyvgart Hytrulo |
| Lilly USA, LLC | $17.69 | 2023 | Emgality, Reyvow |
| Genentech USA, INC. | $15.86 | 2023 | Ocrevus, Enspryng |
| Abbvie INC. | $14.51 | 2023 | Botox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Alshammaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.